Pharma Q3 Results Preview: J&J, Novartis & Roche
Investors are keen to see how J&J's Remicade is holding up to biosimilar competition, especially now that Zytiga generics are on the way. Novartis is likely to play up the potential for new launches like siponimod in multiple sclerosis and Aimovig in migraine, while Roche is expected to continue delivering strong performance for core brands and expansion plans for Tecentriq.
You may also be interested in...
J&J Supports ‘Spirit’ Of DTC Pricing Transparency, But Prefers PhRMA’s Voluntary Approach
Leading off the third quarter earnings calls for biopharma, J&J offered mild support of a proposed HHS policy to require pricing information in direct-to-consumer advertising, but more enthusiastically backed a voluntary approach suggested by PhRMA.
Celltrion’s Rituximab Biosimilar Has Easy US FDA Panel Ride Despite Questions About Narrow Label
Oncologic Drugs Advisory Committee says totality of evidence supports licensure of CT-P10 for three lymphoma indications, but panelists question what additional data would be needed to eventually get Rituxan’s other approved uses, which were carved out for patent and exclusivity reasons, onto the biosimilar’s label.
Key Cancer Data To Be Unveiled At ESMO In Munich
Big pharma and little biotechs are getting ready to pack their bags for Germany where over 2,000 abstracts will be presented at ESMO and the fine details on some major oncology studies will be closely watched.